Rhythm Pharmaceuticals Inc (RYTM) Stock: The One Question Investors Are Asking
Stifel has recently resumed Rhythm Pharmaceuticals Inc (RYTM) stock to Buy rating, as announced on March 5, 2025, according to Finviz. Earlier, on January 2, 2025, Jefferies had initiated the stock to Buy, setting a price target of $80. Oppenheimer also initiated Outperform rating with a price target of $76. Additionally, Guggenheim initiated Buy rating […]
Why Did Guggenheim Give Rhythm Pharmaceuticals Inc (RYTM) Stock Buy Rating?
Guggenheim has recently initiated Rhythm Pharmaceuticals Inc (RYTM) stock to Buy rating, as announced on October 21, 2024, according to Finviz. Earlier, on September 18, 2024, H.C. Wainwright had initiated the stock to Buy, setting a price target of $64. JMP Securities also initiated Mkt Outperform rating with a price target of $64. Additionally, BofA […]
H.C. Wainwright Just Initiated Rhythm Pharmaceuticals Inc (RYTM) Stock—What Does This Mean for Investors?
H.C. Wainwright has recently initiated Rhythm Pharmaceuticals Inc (RYTM) stock to Buy rating, as announced on September 18, 2024, according to Finviz. Earlier, on September 17, 2024, JMP Securities had initiated the stock to Mkt Outperform, setting a price target of $64. BofA Securities also reduced Neutral rating with a price target of $42. Additionally, […]
Why Is Rhythm Pharmaceuticals Inc (RYTM) Stock Surpassing 11.94% from Its 50-Day SMA?
JMP Securities has recently initiated Rhythm Pharmaceuticals Inc (RYTM) stock to Mkt Outperform rating, as announced on September 17, 2024, according to Finviz. Earlier, on May 8, 2024, BofA Securities had reduced the stock from a Buy to Neutral, setting a price target of $42. for RYTM stock. Morgan Stanley also raised their rating with […]
Rhythm Pharmaceuticals Inc (RYTM) Stock: A Deeper Look at Its True Potential
BofA Securities has recently reduced Rhythm Pharmaceuticals Inc (RYTM) stock to Neutral rating, as announced on May 8, 2024, according to Finviz. Earlier, on December 19, 2023, Morgan Stanley had raised the stock rating, setting a price target of $55 for RYTM stock. BofA Securities also raised Buy rating with a price target of $27. […]
How Does Rhythm Pharmaceuticals Inc (RYTM) Stack Up Against Its Industry Peers?
BofA Securities has recently reduced Rhythm Pharmaceuticals Inc (RYTM) stock to Neutral rating, as announced on May 8, 2024, according to Finviz. Earlier, on December 19, 2023, Morgan Stanley had raised the stock rating, setting a price target of $55. for RYTM stock. BofA Securities also raised Buy rating with a price target of $27. […]
Rhythm Pharmaceuticals Inc (RYTM) Stock’s 0.01% Increase This Year: What’s the Story?
BofA Securities has recently reduced Rhythm Pharmaceuticals Inc (RYTM) stock to Neutral rating, as announced on May 8, 2024, according to Finviz. Earlier, on December 19, 2023, Morgan Stanley had raised the stock rating, setting a price target of $55. for RYTM stock. BofA Securities also raised Buy rating with a price target of $ […]
A positive surprise is on the way: Rhythm Pharmaceuticals Inc. (RYTM) Stock
BofA Securities lowered the price target for the Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) stock from “a Buy” to “a Neutral”. The rating was released on May 08, 2024, according to finviz. We previously noted in another research note published on December 19, 2023 by Morgan Stanley that upgraded the stock from an Equal-weight to an Overweight […]
With upside potential, Rhythm Pharmaceuticals Inc. (RYTM) Stock is well-positioned to grow
BofA Securities lowered the price target for the Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) stock from “a Buy” to “a Neutral”. The rating was released on May 08, 2024, according to finviz. We previously noted in another research note published on December 19, 2023 by Morgan Stanley that upgraded the stock from an Equal-weight to an Overweight […]
Rhythm Pharmaceuticals Inc. (RYTM) Stock is expected to generate profits in the near future
BofA Securities lowered the price target for the Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) stock from “a Buy” to “a Neutral”. The rating was released on May 08, 2024, according to finviz. We previously noted in another research note published on December 19, 2023 by Morgan Stanley that upgraded the stock from an Equal-weight to an Overweight […]
